Table 1 VWD patient phenotypes Patient .... | American Society of Hematology

Table 1

VWD patient phenotypes

Patient	VWD diagnosis	Age	Sex	VWF:Ag IU/dL	VWF:RCo IU/dL	FVIII:C IU/dL	VWF:Ag post-DDAVP IU/dL	VWF:RCo post-DDAVP IU/dL	FVIII:C post-DDAVP IU/dL	VWF gene	Blood group
VWD-10	1	58	M	7	8	18	7	10	18	c.2438dupG and c.2281+4A>G (intronic)	B
VWD-8	1	61	F	15	14	68	28	47	283	D75-G178 del	O
VWD-1	1	41	F	13	12	23	39	N.A.	94	I1343V, V1360A, F1369I, S1378F, R1379C	O
VWD-12	1	43	F	22	15	59	90	N.A.	300	Y1584C	O
VWD-13	2A	28	M	38	14	50	142	81	245	R1597W	O
VWD-2	2M	49	F	26	9	48	84	36	150	I1416T	A
VWD-3	2M	27	M	26	6	42	101	48	83	I1416T	N.A.
VWD-17	2M	73	M	14	<5	40	N.A.	N.A.	N.A.	R1315C	B

Patient	VWD diagnosis	Age	Sex	VWF:Ag IU/dL	VWF:RCo IU/dL	FVIII:C IU/dL	VWF:Ag post-DDAVP IU/dL	VWF:RCo post-DDAVP IU/dL	FVIII:C post-DDAVP IU/dL	VWF gene	Blood group
VWD-10	1	58	M	7	8	18	7	10	18	c.2438dupG and c.2281+4A>G (intronic)	B
VWD-8	1	61	F	15	14	68	28	47	283	D75-G178 del	O
VWD-1	1	41	F	13	12	23	39	N.A.	94	I1343V, V1360A, F1369I, S1378F, R1379C	O
VWD-12	1	43	F	22	15	59	90	N.A.	300	Y1584C	O
VWD-13	2A	28	M	38	14	50	142	81	245	R1597W	O
VWD-2	2M	49	F	26	9	48	84	36	150	I1416T	A
VWD-3	2M	27	M	26	6	42	101	48	83	I1416T	N.A.
VWD-17	2M	73	M	14	<5	40	N.A.	N.A.	N.A.	R1315C	B

The parameters defining the clinical phenotypes of the patients studied are displayed. Patients’ plasma VWF:Ag and VWF:RCo at baseline and pre- and post-DDAVP treatment are shown. Sequence changes in the VWF gene of patients are indicated with the predicted amino acid change or, if intronic, the nucleotide change. Normal range for VWF:Ag and VWF:RCo = 50 to 150 IU/dL and for FVIII:C = 45 to 150 IU/dL.

N.A., not available.

View Large

This Feature Is Available To Subscribers Only